Physician profile
Ami Orr
NPI 1215933742
$397.28
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $234 · 2020: $164.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $80.89 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $59.06 | 2019 | |
| Tris Pharma INC | $56.01 | 2020 | |
| Ironshore Pharmaceuticals INC. | $39.32 | 2019 | |
| Kaleo, INC. | $34.46 | 2020 | |
| Pfizer INC. | $31.62 | 2019 | |
| Glaxosmithkline, LLC. | $27.36 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $26.41 | 2019-2020 | |
| Sanofi Pasteur INC. | $16.66 | 2019 | |
| Neos Therapeutics, Lp | $13.96 | 2020 | |
| Adlon Therapeutics L.P. | $11.53 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ami Orr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.